Relay Therapeutics Inc
RLAY
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.69B
Close$
$-1.47
109.6% downside
Current Fair Value
109.6% downsideOvervalued by 109.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.69 Billion |
|---|---|
| Enterprise Value | $2.52 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.61 |
| Beta | 1.75 |
| Outstanding Shares | 179,849,137 |
Return
| Return on Equity | -42.47% |
|---|---|
| Return on Assets | -38.98% |
| Return on Invested Capital | -43.47% |
Valuation & Multiples
| P/E Ratio | -9.27 |
|---|---|
| PEG | 189.21 |
| Price to Sales | - |
| Price to Book Ratio | 5.1 |
| Enterprise Value to Revenue | 235.93 |
| Enterprise Value to EBIT | -8.65 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
$5.58 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$710,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0677▲ 2.18% |
|---|---|
| Total Calls | 1,102,700▲ 77.08% |
| Total Puts | 74,700▲ 161.19% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 106.73%▲ 6.05% |
|---|---|
| Total Invested | $1.82B▲ 24.08% |
| Investors Holding | 245▲ 16.00% |
ESG Score
No data
About Relay Therapeutics Inc
2,020 employeesRelay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.